XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Parties Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 18, 2018
Jan. 26, 2017
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Dec. 31, 2017
Sep. 30, 2017
Sep. 25, 2017
May 26, 2017
Related Parties Transactions (Textual)                  
Amount received from BriVision     $ 4,286,320 $ 4,229,320   $ 4,229,320      
Outstanding loan     950,000 950,000          
Accrued interest     17,960 17,460          
Interest expenses     33,645   $ 19,000        
Aggregate working capital     $ 14,000 7,000          
Interest rate percentage     0.00%            
Stock based compensation expenses     $ 5,626   3,376        
Additional paid-in capital     13,891,382 13,805,936   13,805,936      
Monthly base rent     5,000            
Rent expenses     $ 0   15,000        
Related party transactions, description     Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsianGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. As of March 31, 2018 and December 31, 2017, Everfront only paid $160,000 to AsianGene. AsianGene also agreed to loan the proceeds to the Company for working capital purpose. On January 16, 2018, AsianGene and the Company entered into a loan agreement. Pursuant to the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 15, 2019.            
Chairman [Member]                  
Related Parties Transactions (Textual)                  
Aggregate working capital     $ 100     $ 100      
Interest rate percentage     0.00%     0.00%      
Loan Agreement [Member]                  
Related Parties Transactions (Textual)                  
Total commitment   $ 950,000              
Loan maturity date   Feb. 01, 2018              
Loan agreement, description   The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.              
Co-Dev Agreement [Member]                  
Related Parties Transactions (Textual)                  
Amount received from BriVision     $ 450,000 450,000   $ 450,000     $ 3,000,000
Common stock new issues     2,550,000 2,550,000     $ 3,000,000    
Additional paid-in capital             $ 3,000,000    
Asiangene Corporation [Member]                  
Related Parties Transactions (Textual)                  
Amount received from BriVision     160,000 160,000   160,000      
Outstanding loan     160,000 160,000          
Interest expenses     3,945   0        
BioLite [Member]                  
Related Parties Transactions (Textual)                  
Aggregate working capital     $ 109,220 $ 109,220          
Interest rate percentage     0.00% 0.00%          
BioFirst Collaborative Agreement [Member]                  
Related Parties Transactions (Textual)                  
Due to BioFirst               $ 3,000,000  
YuanGene Corporation [Member]                  
Related Parties Transactions (Textual)                  
Amount received from BriVision     $ 53,000 $ 3,000   3,000      
Outstanding loan     50,000     0      
Accrued interest     1,200     0      
Interest expenses     1,200   $ 0        
Aggregate working capital $ 50,000   $ 3,000     $ 3,000      
Interest rate percentage     0.00%     0.00%      
Related party transactions, description Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 17, 2017.